-+ 0.00%
-+ 0.00%
-+ 0.00%

Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?

Benzinga·04/27/2025 15:46:27
Listen to the news

These eight mid-cap stocks were the best performers in the last week. Are they in your portfolio?

  1. Ascentage Pharma Group Internat (NASDAQ:AAPG) stock jumped 38.35%. The company plans to present data from two clinical studies at the 2025 ASCO Annual Meeting, including an oral presentation for its key assets Lisaftoclax and Alrizomadlin.
  2. Ardagh Metal Packaging (NYSE:AMBP) shares escalated 38.66% after the company reported a year-over-year increase in first-quarter adjusted EPS results and better-than-expected revenue results. Additionally, the company raised its FY25 adjusted EBITDA guidance.
  3. Bitdeer Technologies Group (NASDAQ:BTDR) stock gained 38.19% last week. Shares of crypto-related companies have gained amid a rise in the price of Bitcoin. The cryptocurrency continues to face volatility but has decoupled from risk assets this week and has outperformed Gold.
  4. Pegasystems Inc. (NASDAQ:PEGA) shares upped 32.85% after reporting better-than-expected first-quarter financial results. Several analysts raised the price forecast for the stock.
  5. Impinj, Inc. (NASDAQ:PI) shares increased 31.58% after the company reported better-than-expected financial results and issued second-quarter guidance above estimates. Several analysts revised the price forecast for the stock.
  6. Lufax Holding Ltd (NYSE:LU) stock grew 30.72%, probably amid overall market strength due to March’s strong durable goods orders economic data and President Trump’s announcement that he met with China earlier today.
  7. Tempus AI Inc (NASDAQ:TEM) shares rocketed 30.09% after the company announced a multi-year collaboration with AstraZeneca PLC (NASDAQ:AZN) and Pathos AI.
  8. Kymera Therapeutics (NASDAQ:KYMR) stock was up 28.00%. The company initiated dosing in the BroADen phase 1B clinical trial evaluating KT-621, a potent degrader of STAT6, in patients with moderate to severe atopic dermatitis.

Photo by Piotr Swat via Shutterstock